Table 1.
Correlation among clinicopathological status and the expression of MPRL, pre-miR-483 or miR-483-5p in TSCC patients.
| Characteristics | MPRL(%) | P | pre-miR-483(%) | P | miR-483-5p(%) | P | |||
|---|---|---|---|---|---|---|---|---|---|
| No. of low Expression | No. of high Expression | No. of low Expression | No. of high Expression | No. of low Expression | No. of high Expression | ||||
| Sex | 0.584 | 0.916 | 0.131 | ||||||
| Male | 35(45.5) | 42(54.5) | 32(41.6) | 45(58.4) | 43(55.8) | 34(44.2) | |||
| Female | 27(40.9) | 39(59.1) | 28(42.4) | 38(57.6) | 45(68.2) | 21(31.8) | |||
| Age | 0.291 | 0.664 | 0.352 | ||||||
| <50 | 26(49.1) | 27(50.9) | 21(39.6) | 32(60.4) | 30(56.6) | 23(43.4) | |||
| ≥50 | 36(40.0) | 54(60.0) | 39(43.3) | 51(56.7) | 58(64.4) | 32(35.6) | |||
| Node metastasis | 0.951 | 0.073 | 0.084 | ||||||
| N0 | 28(43.1) | 37(56.9) | 22(33.8) | 43(66.2) | 45(69.2) | 20(30.8) | |||
| N+ | 34(43.6) | 44(56.4) | 38(48.7) | 40(51.3) | 43(55.1) | 35(44.9) | |||
| Clinical stage | 0.658 | 0.119 | 0.607 | ||||||
| Ⅲ | 39(44.8) | 48(55.2) | 41(47.1) | 46(52.9) | 55(63.2) | 32(36.8) | |||
| Ⅳ | 23(41.1) | 33(58.9) | 19(33.9) | 37(66.1) | 33(58.9) | 23(41.1) | |||
| Cisplatin | <0.001 | 0.028 | <0.001 | ||||||
| Sensitive | 21(28.0) | 54(72.0) | 25(33.3) | 50(66.7) | 62(81.6) | 14(18.4) | |||
| Non-sensitive | 41(60.3) | 27(39.7) | 35(51.5) | 33(48.5) | 26(38.8) | 41(61.2) | |||
| Status(60 months) | 0.010 | 0.048 | 0.006 | ||||||
| Survival | 16(29.6) | 38(70.4) | 17(31.5) | 37(68.5) | 41(75.9) | 13(24.1) | |||
| Death | 46(51.7) | 43(48.3) | 43(48.3) | 46(51.7) | 47(52.8) | 42(47.2) | |||